Intermediate or surrogate endpoints for survival can shorten timelines for drug approval. A paper just published on line in Lancet Oncology aimed to assess the value of circulating tumor cell (CTC) co… more →
THE "NEW" PROSTATE CANCER INFOLINKSitemaster wrote 5 months ago: Intermediate or surrogate endpoints for survival can shorten timelines for drug approval. A paper ju … more →
Sitemaster wrote 8 months ago: Many reader will already have seen or heard reports of the demise of the SELECT prostate cancer prev … more →